Mohamad A. Salkeni

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

Trisha M. Wise‐Draper, Ganesh Moorthy, Mohamad A. Salkeni et al. · Targeted Oncology · 2017 · 112 citations · Full text

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

Jame Abraham, A.J. Montero, Rachel C. Jankowitz et al. · Journal of Clinical Oncology · 2019 · 79 citations · Full text

Lipopolysaccharide Impairs Blood–Brain Barrier P-glycoprotein Function in Mice Through Prostaglandin- and Nitric Oxide-Independent Pathways

Mohamad A. Salkeni, Jessica Lynch, Tulin Otamis-Price et al. · Journal of Neuroimmune Pharmacology · 2008 · 68 citations · Full text

Molecular Physiology, Biochemistry, Medicine +8

Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients

Mohamad A. Salkeni, Ahmad Zarzour, Tracy Y. Ansay et al. · Journal of Neuro-Oncology · 2013 · 56 citations

Tumor Biology, Brain Tumor Patients, Medicine +9